Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Eur Acad Dermatol Venereol ; 35(5): 1119-1132, 2021 May.
Artigo em Inglês | MEDLINE | ID: mdl-33326646

RESUMO

BACKGROUND AND OBJECTIVES: The incidence of melanoma is increasing. This places significant burden on societies to provide efficient cancer care. The European Cancer Organisation recently published the essential requirements for quality melanoma care. The present study is aimed for the first time to roughly estimate the extent to which these requirements have been met in Europe. MATERIALS AND METHODS: A web-based survey of experts from melanoma centres in 27 European countries was conducted from 1 February to 1 August 2019. Data on diagnostic techniques, surgical and medical treatment, organization of cancer care and education were collected and correlated with national health and economic indicators and mortality-to-incidence ratio (MIR) as a surrogate for survival. Univariate linear regression analysis was performed to evaluate the correlations. SPSS software was used. Statistical significance was set at P < 0.05. RESULTS: The MIR was lower in countries with a high health expenditure per capita and with a higher numbers of general practitioners (GPs) and surgeons (SURG) per million inhabitants. In these countries, GPs and dermatologists (DER) were involved in melanoma detection; high percentage of DER used dermatoscopy and were involved in the follow-up of all melanoma stages; both medical oncologists (ONC) and dermato-oncologists administered systemic treatments; and patients had better access to sentinel lymph node biopsy and were treated within multidisciplinary tumour boards. CONCLUSION: Based on these first estimates, the greater involvement of GPs in melanoma detection; the greater involvement of highly trained DER in dermatoscopy, dermatosurgery, follow-up and the systemic treatment of melanoma; and the provision of ongoing dermato-oncology training for pathologists, SURG, DER and ONC are necessary to provide an optimal melanoma care pathway. A comprehensive analysis of the melanoma care pathway based on clinical melanoma registries will be needed to more accurately evaluate these first insights.


Assuntos
Melanoma , Europa (Continente) , Gastos em Saúde , Humanos , Incidência , Melanoma/diagnóstico , Melanoma/epidemiologia , Melanoma/terapia , Inquéritos e Questionários
2.
Eur J Cancer ; 104: 201-209, 2018 11.
Artigo em Inglês | MEDLINE | ID: mdl-30388700

RESUMO

According to data from recent studies from Europe, a large percentage of patients have restricted access to innovative medicines for metastatic melanoma. Melanoma World Society and European Association of Dermato-oncology conducted a Web-based survey on access to first-line recommended treatments for metastatic melanoma by current guidelines (National Comprehensive Center Network, European Society for Medical Oncology [ESMO] and European Organization for Research and Treatment of Cancer/European Association of Dermato-oncology/European dermatology Forum) among melanoma experts from 27 European countries, USA, China, Australia, Argentina, Brazil, Chile and Mexico from September 1st, 2017 to July 1st, 2018. Data on licencing and reimbursement of medicines and the number of patient treated were correlated with the data on health expenditure per capita (HEPC), Mackenbach score of health policy performance, health technology assessment (HTA), ASCO and ESMO Magnitude of clinical benefit scale (ESMO MCBS) scores of clinical benefit and market price of medicines. Regression analysis for evaluation of correlation between the parameters was carried out using SPSS software. The estimated number of patients without access in surveyed countries was 13768. The recommended BRAFi + MEKi combination and anti-PD1 immunotherapy were fully reimbursed/covered in 19 of 34 (55.8%) and 17 of 34 (50%) countries, and combination anti-CTLA4+anti-PD1 in was fully covered in 6 of 34 (17.6%) countries. Median delay in reimbursement was 991 days, and it was in significant correlation with ESMO MCBS (p = 0.02), median market price (p = 0.001), HEPC and Mackenbach scores (p < 0.01). Price negotiations or managed entry agreements (MEAs) with national authorities were necessary for reimbursement. In conclusion, great discrepancy exists in metastatic melanoma treatment globally. Access to innovative medicines is in correlation with economic parameters as well as with healthcare system performance parameters. Patient-oriented drug development, market access and reimbursement pathways must be urgently found.


Assuntos
Drogas em Investigação/provisão & distribuição , Melanoma/secundário , Ensaios Clínicos como Assunto/estatística & dados numéricos , Ensaios de Uso Compassivo , Custos de Medicamentos , Drogas em Investigação/economia , Drogas em Investigação/uso terapêutico , Europa (Continente) , Produto Interno Bruto , Fidelidade a Diretrizes , Prioridades em Saúde , Desenvolvimento Humano , Humanos , América Latina , Melanoma/tratamento farmacológico , Melanoma/economia , Melanoma/epidemiologia , Guias de Prática Clínica como Assunto , Honorários por Prescrição de Medicamentos , Mecanismo de Reembolso , Federação Russa , Fatores Socioeconômicos , Inquéritos e Questionários , Aquisição Baseada em Valor
3.
Eur J Cancer ; 75: 313-322, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-28264791

RESUMO

BACKGROUND: Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among different European countries. We analysed the availability of these innovative therapies in Europe and estimated the number of patients without access to first-line recommended treatment per current guidelines of professional entities such as the European Society for Medical Oncology (ESMO), the European Organisation for Research and Treatment of Cancer (EORTC), the European Association of Dermato-Oncology (EADO), and European Dermatology Forum (EDF). MATERIALS AND METHODS: Web-based online survey was conducted in 30 European countries with questions about the treatment schedules from 1st May 2015 to 1st May 2016: number of metastatic melanoma patients, registration and reimbursement of innovative medicines (updated data, as of 1st October 2016), percentage of patients treated and availability of clinical studies and compassionate-use programmes. RESULTS: The recommended BRAF inhibitor (BRAFi) + MEK inhibitor (MEKi) combination was both registered and fully reimbursed in 9/30 (30%) countries, and in 13/30 (43%) (all from Eastern Europe) not reimbursed. First-line immunotherapy with anti-PD1 antibodies was registered and fully reimbursed in 14/30 (47%) countries, while in 13/30 (43%) (all from Eastern Europe) not reimbursed. It was estimated that in Europe 19,600 patients with metastatic melanoma are treated, and 5238 (27%) do not have access to recommended first-line therapy. Significant correlation was found between human development index (HDI, UNDP report 2015), (r = 0.662; p < 0.001), health expenditure per capita (r = 0.695; p < 0.001) and the Mackenbach score of health policy performance (r = 0.765; p < 0.001) with the percentage of patients treated with innovative medicines and a number of reimbursed medicines. CONCLUSIONS: Great discrepancy exists in metastatic melanoma treatment across Europe. It is crucial to increase the awareness of national and European policymakers, oncological societies, melanoma patients' associations and pharma industry.


Assuntos
Disparidades em Assistência à Saúde/estatística & dados numéricos , Melanoma/terapia , Neoplasias Cutâneas/terapia , Terapias em Estudo/estatística & dados numéricos , Acrilonitrila/análogos & derivados , Acrilonitrila/economia , Acrilonitrila/provisão & distribuição , Compostos de Anilina/economia , Compostos de Anilina/provisão & distribuição , Anticorpos Monoclonais Humanizados/economia , Anticorpos Monoclonais Humanizados/uso terapêutico , Europa (Continente)/epidemiologia , Feminino , Acessibilidade aos Serviços de Saúde/economia , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Disparidades em Assistência à Saúde/economia , Humanos , Imunoterapia/economia , Imunoterapia/estatística & dados numéricos , Masculino , Melanoma/economia , Melanoma/epidemiologia , Receptor de Morte Celular Programada 1/antagonistas & inibidores , Proteínas Proto-Oncogênicas B-raf/antagonistas & inibidores , Mecanismo de Reembolso/estatística & dados numéricos , Neoplasias Cutâneas/economia , Neoplasias Cutâneas/epidemiologia , Terapias em Estudo/economia
4.
J Hypertens ; 15(12 Pt 1): 1471-9, 1997 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-9431854

RESUMO

OBJECTIVE: To characterize the effect of beta-adrenergic activation on renal production of renin in the intact organism. DESIGN AND METHODS: Renal expression of renin [renin messenger RNA (mRNA)], plasma renin activity (PRA), inactive renin level, intrarenal renin distribution (immunohistochemistry), and the time course of activation of renin as well as hemodynamic parameters were determined during the subcutaneous infusion of isoproterenol (ISO) into rats. To examine whether beta-adrenergic activation of the renin system is modulated by the rate of salt intake rats were fed diets with normal, low and high salt contents. RESULTS: Systolic blood pressure was not altered. PRA was elevated as much as fourfold after 40 h of ISO infusion. Although renal renin mRNA levels were elevated dose-dependently up to 4.2-fold, no significant recruitment of renin-containing cells could be detected. The time course of PRA revealed a marked transient rise of PRA during 6 h of ISO infusion with a subsequent decline. Inactive renin level was elevated during 3 to 18 h of ISO infusion. In contrast, renin mRNA level increased steadily with a lag phase of 3 h. Infusion of ISO increased PRA and renin mRNA level under a high-salt diet, but had no additional effect either on PRA or on renin mRNA level under low-salt diet. CONCLUSION: Activation of beta-adrenergic receptors is a powerful stimulus of renin secretion and renin gene expression in juxtaglomerular cells in vivo, albeit the kinetics of upregulation of renin secretion and renin expression are markedly different. Therefore, the sympathetic tone might be a major factor determining the activity of the renin system in vivo. The ability of adrenergic agonists to stimulate the renin system appears to be modulated by the steady-state level of salt intake.


Assuntos
Rim/metabolismo , Renina/metabolismo , Antagonistas Adrenérgicos beta/farmacologia , Animais , Dieta Hipossódica , Imunofluorescência , Hemodinâmica/efeitos dos fármacos , Isoproterenol/farmacologia , Masculino , RNA Mensageiro/metabolismo , Ratos , Ratos Wistar , Renina/sangue , Renina/genética , Fatores de Tempo , Distribuição Tecidual
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...